Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 5/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19658176 | 1.00 | TP53 (0.35) | TP53CYP3A4MGLL | |
| SCHEMBL20848195 | 0.96 | MGLL (0.33) | TP53CYP3A4MGLL | |
| SCHEMBL18751705 | 0.96 | MGLL (0.33) | TP53CYP3A4MGLL | |
| SCHEMBL19658181 | 0.92 | MGLL (0.33) | MGLL | |
| SCHEMBL19658322 | 0.92 | MGLL (0.33) | MGLL | |
| SCHEMBL18751704 | 0.92 | MGLL (0.33) | MGLL | |
| SCHEMBL13366915 | 0.91 | HTT (0.38) | — | |
| SCHEMBL24102291 | 0.88 | EPHX1 (0.43) | MGLL | |
| SCHEMBL21100434 | 0.85 | MGLL (0.33) | MGLL | |
| SCHEMBL17776326 | 0.85 | MGLL (0.33) | MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3922260-A2 | INSULIN RECEPTOR PARTIAL AGONISTS AND GLP-1 ANALOGUES | MERCK SHARP & DOHME CORP. (US) | 2021-12-15 | — | — | EP | disclosed |
| US-11058775-B2 | Insulin dimer-incretin conjugates | MERCK SHARP & DOHME CORP. (US) | 2021-07-13 | — | — | US | disclosed |
| US-10953076-B2 | Insulin receptor partial agonists and GLP-1 analogues | MERCK SHARP & DOHME CORP. (US) | 2021-03-23 | — | — | US | disclosed |
| US-10800827-B2 | Insulin receptor partial agonists | MERCK SHARP & DOHME CORP. (US) | 2020-10-13 | — | — | US | disclosed |
| EP-3221343-B1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME (US) | 2020-09-16 | — | — | EP | disclosed |
| EP-3666792-A2 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2020-06-17 | — | — | EP | disclosed |
| EP-3660040-A2 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2020-06-03 | — | — | EP | disclosed |
| EP-3660041-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2020-06-03 | — | — | EP | disclosed |
| US-20190192675-A1 | INSULIN DIMER-INCRETIN CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2019-06-27 | — | — | US | disclosed |
| US-20190142906-A1 | INSULIN RECEPTOR PARTIAL AGONISTS AND GLP-1 ANALOGUES | MERCK SHARP & DOHME CORP. (US) | 2019-05-16 | — | — | US | disclosed |
| US-20190092833-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2019-03-28 | — | — | US | disclosed |
| US-10183981-B2 | Insulin receptor partial agonists | MERCK SHARP & DOHME LLC | 2019-01-22 | — | — | US | disclosed |
| US-10017556-B2 | Insulin receptor partial agonists | MERCK SHARP & DOHME CORP. (US) | 2018-07-10 | — | — | US | disclosed |
| US-10017556-B2 | Insulin receptor partial agonists | MERCK SHARP & DOHME CORP. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20170355743-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-12-14 | — | — | US | disclosed |
| US-20170355743-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-12-14 | — | — | US | disclosed |
| US-20170107268-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-04-20 | — | — | US | disclosed |
| US-20170107268-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10800827-B2 | Insulin receptor partial agonists | INSR, GPR119, IRS1 | TP53 3535/4885CYP3A4 2335/4885MGLL 2105/4885 |
| US-20190192675-A1 | INSULIN DIMER-INCRETIN CONJUGATES | IAPP, GLP1R, GIPR | TP53 3992/4885CYP3A4 4127/4885MGLL 1688/4885 |
| US-20190092833-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | INSR, GPR119, IRS1 | TP53 3535/4885CYP3A4 2335/4885MGLL 2105/4885 |
| US-11058775-B2 | Insulin dimer-incretin conjugates | IAPP, GLP1R, GIPR | TP53 3992/4885CYP3A4 4127/4885MGLL 1688/4885 |
| US-20190142906-A1 | INSULIN RECEPTOR PARTIAL AGONISTS AND GLP-1 ANALOGUES | GLP1R, GIPR, IAPP | TP53 4664/4885CYP3A4 3154/4885MGLL 526/4885 |
| US-10953076-B2 | Insulin receptor partial agonists and GLP-1 analogues | GLP1R, GIPR, IAPP | TP53 4664/4885CYP3A4 3154/4885MGLL 526/4885 |
| US-10183981-B2 | Insulin receptor partial agonists | INSR, GPR119, IRS1 | TP53 3535/4885CYP3A4 2335/4885MGLL 2105/4885 |
| US-20170355743-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | INSR, GPR119, IRS1 | TP53 3535/4885CYP3A4 2335/4885MGLL 2105/4885 |
| US-10017556-B2 | Insulin receptor partial agonists | INSR, GPR119, IRS1 | TP53 3535/4885CYP3A4 2335/4885MGLL 2105/4885 |
| US-20170107268-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | INSR, GPR119, IRS1 | TP53 3535/4885CYP3A4 2335/4885MGLL 2105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.